Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC).

被引：1

作者：

Young, Rha Sun ^{[1
]}

Lee, Jii Bum ^{[1
]}

Kim, Hyo Song ^{[1
]}

Jung, Minkyu ^{[1
]}

Lee, Choong-kun ^{[1
]}

Park, Sook Ryun ^{[2
]}

Koo, Dong-Hoe ^{[3
]}

Lee, Hyun Woo ^{[4
]}

Bae, Woo Kyun ^{[5
,6
]}

Jeung, Hei Cheul ^{[7
]}

Chung, Hyun Cheol ^{[1
]}

机构：

[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med,Div Med Oncol, Seoul, South Korea

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Oncol, Seoul, South Korea

[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med,Div Hematol & Oncol, Seoul, South Korea

[4] Ajou Univ, Sch Med, Dept Hematol Oncol, Suwon, South Korea

[5] Chonnam Natl Univ, Sch Med, Jeonnam, South Korea

[6] Hwasun Hosp, Jeonnam, South Korea

[7] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2021-CT159

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT159

引用

页数：1

共 3 条

[1] A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)-positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed
An, Jusheng
Zhang, Yunyan
Feng, Mei
Zhang, Keqiang
Zhu, Jianqing
He, Aiqin
Li, Xiumin
Peng, Jin
Wang, Xinwen
Zhang, Hongping
Kong, Weimin
Li, Guiling
Yuan, Jianlin
Yu, Shiying
Liu, Hu
Ma, Cailing
Chen, Hongmin
Shen, Liangfang
Xie, Fan
Wu, Lingying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC).
Mueller, Daniel Wilhelm
Siegler, Gabriele Margareta
de Toni, Enrico
Lindig, Udo
Siebler, Jurgen
Walker, Martin
Al-Batran, Salah-Eddin
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
Cheng, Ying
Zhang, Panpan
Lu, Ming
Chen, Zhendong
Song, Lijie
Shi, Si
Ye, Feng
Zhang, Xing
Liu, Baorui
Ji, Dongmei
Zhang, Yanqiao
Su, Weiguo
Shi, Michael
Fan, Songhua
Tan, Panfeng
Zhong, Chen
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)

← 1 →